Abstract:Objective To identify the significance of genomic markers of drug sensitivity for individualized therapy in children with extracranial malignant solid tumors.Methods The surgical specimens and peripheral blood samples in 38 children with refractory extracranial malignant solid tumors were collected between Apri.2011 and Apri.2013.The genomic markers of anticancer drug sensitivity were examined,including gene expression or mutation of 15 chemotherapeutic agents and two targeted drugs by methods of immunohistochemical staining,enzyne linked immunosorbent assay,fluorescence in situ hybridization,polymerase chain reaction amplification and sequencing.Results Among all of 38 samples,35 were firstly surgical specimens and 3 secondary surgical specimens,and 3 of them were peripheral blood samples.The tumor tissue of the targets for chemotherapeutic agents such as topoisomerase Ⅱ A (TOPO Ⅱ A) in 34 cases,Tubulinβ3 in 32 cases,excision repair cross-complementing 1 (ERCC1) in 28 cases,topoisomerase Ⅰ (TOPO Ⅰ) in 28 cases,O6-methylguanine-DNA methyltransferase (MGMT) in 20 eases,thymidylate synthase (TS) in 13 cases and ribonucleotide reductase M 1 (RRM1)in 6 cases were examined.The 68.75％ samples were fluorouracil and pemetrexed sensitivity,66.67％ samples gemcitabine sensitivity,56.25％ samples vincristine(VCR) sensitivity;while 67.65％ had low sensitivity to anthracycline/etoposide,64.29％ had low sensitivity to platinum and topotecan/irinotecan;63.64％ had low sensitivity to temozolomide(TMZ).What's more,the peripheral blood of the targets for chemotherapeutic agents such as CYP2C9 * 3 genotypes in 33 cases and dihydrofolate reductase (DHFR C829T) genotypes in 14 cases were detected,and found that 100.00％ and 93.33％ of samples had cyclophosphamide and methotrexate sensitivity,respectively.Furthermore,peripheral blood was used to test the targets for chemotherapy toxicity and found that 100.00％ of cyclophosphamide and methotrexate toxicity were weak,76.19％ of irinotecan and etoposide toxicity was weak.Additionally,tumor tissues of the genomic markers for targeted drugs,such as vascular endothelial growth factor receptor-2 (VEGFR-2) in 15 cases,epidermal growth factor receptor (EGFR) in 5 cases and intercellular cell adhesion molecule-1 in 10 cases,were examined.Up to 68.00％ samples were detected sensitive to Bevacizumab.EGFR was not amplified in any case studied and Tyrosine kinase inhibitor response was invalid.On the basis of the above test results,therapeutic strategy for the patients who had unsatisfactory curative effect and then they achieved preliminary effect were promptly adjusted.Conclusions This study firstly examined the genomic markers of drug sensitivity in children with extracranial malignant solid tumors,which provide laboratory basis for individualized treatment selection and drug side effects prediction.

Analysis of Drug Sensitivity of Variant Antineoplastic Drugs on Retinoblastoma Cells in Vitro

[Assessment of Six Drug Sensitivities in Established Cell Lines of SO-Rb50 and SO-Rb70].

A study on the toxicity of three radiosensitizers on retinoblastoma cells by MTT assay

Analysis of Drug Sensitivity and Its Guidance in Clinic in 61 Cases of Breast Cancer Cell

Expression of multidrug resistant gene and multidrug resistant associated protein in retinoblastoma

Mechanism of All-Transretinoic Acid Increasing Retinoblastoma Sensitivity to Vincristine.

Research and Exploratory of Chemotherapy Drugs Sensitivity Tests in Liver Cancer

Clinical efficacy and prognostic factors of chemoreduction combined with topical treatment for advanced intraocular retinoblastoma

Research on the Chemotherapeutic Sensitivity of Cerebral Gliomas in Vitro

[Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].

Advance in the chemotherapy resistance of retinoblastoma

Expression of Multidrug-Resistance Associated Proteins in Human Retinoblastoma Treated by Primary Enucleation

Chemosensitivity in vitro of 25 anti-cancer drugs to primary cultured human breast cancer cells

P1.02-048 Somatic Mutation Analysis of RB1 Gene in Chinese Non-Small Cell Lung Cancer Patients

Study on the Sensitivity of Primary Glioma Cell to Chemotherapeutic Agents in Vitro

Primary identification of genomic markers of drug sensitivity for individualized therapy in 38 children with extracranial malignant solid tumors

Characterization of etoposide- and cisplatin-chemoresistant retinoblastoma cell lines

The Potential Benefit of Three vs. Six Cycles of Carboplatin, Etoposide, and Vincristine in Postenucleation High-Risk Patients with IRSS Stage I Retinoblastoma.

Primary Identification of Genomic Markers of Drug Sensitivity for Individualized Therapy in Children with Neuroblastoma of Ⅲ-Ⅳ Stage

Study on Chemosensitivity of Peripheral Blood Lymphocytes and Tumor Cells of Tumor Patients in Vitro

Research on the chemotherapeutic sensitivity of cerebral gliomas